AMARILLO, Texas, Oct. 14, 2011 /PRNewswire/ -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today provided an update on company activities.
Oral Interferon Phase 2 Hepatitis C Study Nearing CompletionABI's oral interferon research continues. Results from a Phase 2, dose-ranging study of oral interferon for the prevention of relapse in hepatitis C patients are expected in the first quarter of 2012. A Phase 2 study of oral IFN, in combination with Tamiflu, for the treatment of influenza infection will be conducted during the upcoming flu season in Taiwan. Results are expected in the third quarter of 2012.
New Oral Interferon Studies Planned in Hepatitis B and CancerTwo new oral interferon studies are expected to start in 2012. The first will be a Phase 2 study for treatment and prevention of relapse in patients with chronic hepatitis B infection. The second will be a pilot trial to evaluate oral interferon as adjunctive therapy for certain types of cancer.
Launch of Product to Enhance Health of Animals in Shelters Planned by Year's EndThere are approximately 3,500 animal shelters in the United States. Whenever animals from different sources and backgrounds, and often with an incomplete vaccination history, are placed into these shelters, upper respiratory illness (URI) with severe cough and fever is a common occurrence. Digestive tract infections also frequently develop in these shelters. Both URI and diarrhea cause severe illness and an unacceptably high rate of death in sheltered animals.
ABI's goal is to provide a product to help address these common health problems afflicting the nation's animal shelters. More than 20 years of research and observations have resulted in the creation of an inexpensive oral formulation that can be given to companion animals upon arrival at shelters to improve their health and enhance their immunity. Product launch is expected by the end of the year.
About Amarillo Biosciences
|SOURCE Amarillo Biosciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved